TLR9 and neoplasm: Combining a TLR9 agonist (CpG) with a polyspecific integrin‐binding peptide (PIP) to generate a tumor‐targeting immunomodulator, referred to as PIP‐CpG, triggered tumor regression and prolonged the survival of mice with BC tumors.